CELLECTISAct. Nom. News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

01.11.23	Cellectis to Report Third Quarter 2023 Financial Results on November 6, 2023 (GlobeNewswire)
01.11.23	CELLECTIS-Aktie +152 Prozent: AstraZeneca investiert in CELLECTIS - AstraZeneca-Aktie höher (Dow Jones) Der britische Pharmakonzern AstraZeneca will 245 Millionen US-Dollar investieren, um bei dem französischen Biotech-Unternehmen CELLECTIS einzusteigen» mehr
01.11.23	Cellectis Announces Strategic Collaboration and Investment Agreements with AstraZeneca (GlobeNewswire)
31.10.23	Cellectis Presents Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting (GlobeNewswire)
24.10.23	Cellectis to Present Pre-Clinical Data on HSPC Gene Therapy Program and Comprehensive Analysis of TALE-BE at the ESGCT 30th Annual Congress (GlobeNewswire)
03.10.23	Monthly information on share capital and company voting rights (GlobeNewswire)
27.09.23	Cellectis to Present Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting (GlobeNewswire)
05.09.23	Monthly information on share capital and company voting rights (GlobeNewswire)
07.08.23	Cellectis Provides Full Report for Second Quarter 2023 Financial Results (GlobeNewswire)
02.08.23	Ausblick: CELLECTISAct Nom veröffentlicht Zahlen zum vergangenen Quartal (finanzen.net)
01.08.23	Monthly information on share capital and company voting rights (GlobeNewswire)
27.07.23	Cellectis to Report Second Quarter 2023 Financial Results on August 3, 2023 (GlobeNewswire)
12.07.23	Cellectis Appoints Dr. Cécile Chartier, Ph.D. to its Board of Directors (GlobeNewswire)
05.07.23	Monthly information on share capital and company voting rights (GlobeNewswire)
28.06.23	Cellectis S.A. Reports Results from Annual Shareholders’ General Meeting Held on June 27, 2023 (GlobeNewswire)
13.06.23	Monthly information on share capital and company voting rights (GlobeNewswire)
09.06.23	Cellectis Presents Updated Clinical and Translational Data on BALLI-01 at the European Hematology Association (EHA) 2023 (GlobeNewswire)
05.06.23	Cellectis Showcased Preclinical Data at an Oral Presentation and Two Poster Presentations at the 29th International Society for Cell & Gene Therapy (ISCT 2023) Annual Event (GlobeNewswire)
31.05.23	Cellectis Publishes an Article in Cancer Immunology Research Demonstrating Preclinical Evidence of UCART20x22 Product Candidate to Target a Broad Spectrum of Patients with B-cell Malignancies (GlobeNewswire)
17.05.23	Cellectis Presents Clinical Data on AMELI-01 and Preclinical Data on Multiplex Engineering for Superior Generation of CAR T-cells at ASGCT 2023 (GlobeNewswire)
12.05.23	Cellectis Publishes Article in Frontiers in Immunology Unveiling Pre-Clinical Data on a Novel Treatment Paradigm for Successful CAR T Immunotherapy Against Stroma-rich Solid Tumors (GlobeNewswire)
11.05.23	Cellectis Announces Poster Presentation on BALLI-01 at the European Hematology Association (EHA) 2023 (GlobeNewswire)
10.05.23	Monthly information on share capital and company voting rights (GlobeNewswire)
04.05.23	Cellectis Provides Business Update and Reports Financial Results for First Quarter 2023 (GlobeNewswire)
03.05.23	Ausblick: CELLECTISAct Nom präsentiert Quartalsergebnisse (finanzen.net)
02.05.23	Cellectis Announces Oral Presentation on AMELI-01 and Poster Presentation on Multiplex Engineering for Superior Generation of CAR T-cells at the American Society of Gene and Cell Therapy (ASGCT) Annua (GlobeNewswire)
27.04.23	Cellectis to Report First Quarter 2023 Financial Results on May 4, 2023 (GlobeNewswire)
24.04.23	Cellectis Implements CLLS52 for the First Time in the Clinic with Sanofi’s Alemtuzumab (GlobeNewswire)
17.04.23	Cellectis Presents Preclinical Data on TALEN®-edited MUC1 CAR T-cells to Enhance Efficacy in Targeting Triple Negative Breast Cancer at the American Association for Cancer Research (AACR) Annual Meeti (GlobeNewswire)
12.04.23	Monthly information on share capital and company voting rights (GlobeNewswire)
11.04.23	Cellectis Announces Dosing of the First Patient in Europe with its In-house Manufactured Product Candidate UCART22 (GlobeNewswire)
04.04.23	Cellectis enters into warrant agreement with the European Investment Bank related to credit facility agreement and announces the drawdown of the first tranche of €20 million (GlobeNewswire)
15.03.23	Monthly information on share capital and company voting rights (GlobeNewswire)
14.03.23	Cellectis Announces Poster Presentation on TALEN®-edited MUC1 CAR T-cells Targeting Triple Negative Breast Cancer at the American Association of Cancer Research (AACR) Annual Meeting (GlobeNewswire)
07.03.23	Ausblick: CELLECTISAct Nom legt Zahlen zum jüngsten Quartal vor (finanzen.net)
06.03.23	Calyxt, Inc. Reports its Fourth Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
01.03.23	Cellectis to Report Fourth Quarter and Year-End 2022 Financial Results on March 8, 2023 (GlobeNewswire)
09.02.23	Monthly information on share capital and company voting rights (GlobeNewswire)
02.11.22	Ausblick: CELLECTISAct Nom legt Quartalsergebnis vor (finanzen.net)
03.08.22	Ausblick: CELLECTISAct Nom veröffentlicht Zahlen zum vergangenen Quartal (finanzen.net)
11.05.22	Ausblick: CELLECTISAct Nom gibt Ergebnis zum abgelaufenen Quartal bekannt (finanzen.net)
02.03.22	Ausblick: CELLECTISAct Nom vermeldet Zahlen zum jüngsten Quartal (finanzen.net)
03.11.21	Ausblick: CELLECTISAct Nom stellt Quartalsergebnis zum abgelaufenen Jahresviertel vor (finanzen.net)
03.08.21	Ausblick: CELLECTISAct Nom legt Quartalsergebnis vor (finanzen.net)
02.03.21	Ausblick: CELLECTISAct Nom veröffentlicht Zahlen zum vergangenen Quartal (finanzen.net)
04.08.20	Ausblick: CELLECTISAct Nom stellt Ergebnisse des abgelaufenen Quartals vor (finanzen.net)
10.03.20	US Patent Covering CRISPR-Edited Allogeneic CAR T-Cells Granted to Cellectis (Businesswire)
04.03.20	Cellectis Provides Business Update and Reports 4th Quarter and Full Year 2019 Financial Results (Businesswire)
04.03.20	Cellectis and Servier Execute the Amendment Confirming the Expansion of Their Collaboration on UCART19 Products (Businesswire)
03.03.20	Ausblick: CELLECTISAct Nom gewährt Anlegern Blick in die Bücher (finanzen.net)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

UBS Group	27.65	2.14 %	K V
Novartis	88.82	1.30 %	K V
Part Grp Hldg	1’233.00	1.23 %	K V
Kuehne+Nagel Int	207.50	1.22 %	K V
Lonza Grp	538.00	1.05 %	K V
Swisscom	503.00	0.40 %	K V
Sonova Hldg	296.60	0.34 %	K V
Swiss Life Hldg	697.40	0.11 %	K V
Zurich Insur Gr	539.60	0.11 %	K V
Holcim	87.40	0.02 %	K V

Nachrichten zu CELLECTISAct. Nom.

Aktien Top/Flop

Meistgelesene Nachrichten